Table 2 subgroup analysis of the included studies for outcome remyelination.

From: Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis

Subgroup Comparisons Effect estimate [95% CI] I2
Overall 110 1.61 [1.26, 1.97] 85%
MS model
Cuprizone 66 1.61 [1.16, 2.07] 83%
Ethidium bromide 16 1.67 [0.68, 2.65] 87%
Lysolecithin 28 1.60 [0.90, 2.30] 86%
Method
Electron microscopy 32 1.73 [1.05, 2.40] 87%
MBP immuno-staining 26 2.16 [1.44, 2.87] 82%
Luxol fast blue 17 1.85 [0.97, 2.73] 79%
H&E lesion area 5 5.17 [2.83, 7.51] 92%
MOG immune-staining 2 3.29 [0.23, 6.35] 85%
Therapeutic regimen
therapeutically 102 1.67 [1.30, 2.04] 84%
  1. The effect estimate was displayed by the standardized mean difference (SMD) and 95% confidence intervals (CIs). No significant differences were found in the subgroup analyses. Abbreviations: MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein.